newsfilter
← Latest News
GlobeNewswire·

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of